Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth
季度營業收入同比增長10%，環比增長20%，標誌着連續四個季度同比增長
Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver
更高利潤率、持續的耗材營收超過讀卡器營收，成爲主要推動力
Completed in-clinic portion of FDA 510(k) clinical study plan, on track to submit to FDA by year-end
完成FDA 510(k)臨床研究計劃中診所部分，在年底前將提交給FDA
Expanded distribution network in Saudi Arabia
在沙特阿拉伯擴張分銷網絡
Initial review of PK study results show fingerprint sweat strongly aligns to blood and oral fluid, results expected in November
Pk研究結果的初步審查顯示，指紋汗液與血液和口腔液體非常吻合，預計在11月公佈結果。
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal first quarter ended September 30, 2024, and provided a business update.
紐約，2024年11月07日（環球新聞社） - 智能生物解決方案公司（納斯達克股票代碼：INBS）（「INBS」或「公司」）是一家提供智能、快速、無創檢測解決方案的醫療技術公司，今日公佈了截至2024年9月30日的財政第一季度財務業績，並提供了業務更新。
"We've kicked off another strong year with 10% growth in our first quarter compared to the previous year, marking our fourth consecutive quarter of year-on-year growth. As our active accounts continue to grow, so do our cartridge sales, which have surpassed our reader revenue. This shift improves our margins and strengthens our business foundation," said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. "With clinical testing now complete, we're on track to submit our 510(k) package to the FDA by the end of the calendar year. We look forward to sharing our clinical results soon, with our pharmacokinetic study ("PK study") results expected in November. These findings are anticipated to confirm sweat's viability as a drug screening method."
"我們在與上一年同期相比的第一季度實現了10%的增長，標誌着我們連續第四個季度實現同比增長。隨着活躍帳戶繼續增長，我們的芯片銷售量也在增加，已超過我們的讀卡器收入。這種轉變提高了我們的利潤率，並加強了我們的業務基礎，" 智能生物解決方案公司總裁兼首席執行官哈里·西梅奧尼蒂斯（Harry Simeonidis）表示。"隨着臨床測試的完成，我們計劃在本年度年底前向FDA提交我們的510(k)申請。我們期待即將分享我們的臨床結果，預計Pk研究結果將於11月公佈。預計這些發現將證實汗液作爲藥物篩查方法的可行性。"
"Our focus on higher-margin cartridge sales and strategic global expansion is creating a solid foundation for revenue growth and financial stability," added Spiro Sakiris, CFO of Intelligent Bio Solutions. "Our expanding distributor network enables us to meet rising global demand. With a 15% increase in international sales, we are on track to achieve our strategic goal of broadening our global reach and supporting workplace safety worldwide."
"我們專注於更高毛利率的芯片銷售和戰略全球擴張，爲營收增長和財務穩定打下了堅實基礎，" 智能生物解決方案公司首席財務官斯皮羅·薩基里斯（Spiro Sakiris）補充道。"我們不斷擴大的分銷網絡使我們能夠滿足日益增長的全球需求。隨着國際銷售增長15％，我們正朝着擴大全球版圖並全力支持全球職場安全的戰略目標邁進。"
Throughout the quarter, INBS announced the completion of the in-clinic portion of its FDA 510(k) clinical study plan. An initial review of the PK study data shows that fingerprint sweat aligns strongly with blood and oral fluid, demonstrating its reliability for drug detection.
在本季度中，INBS宣佈完成了其FDA 510(k)臨床研究計劃的臨床部分。對Pk研究數據的初步審查顯示，指紋汗液與血液和口腔液體高度一致，表明其在藥物檢測中的可靠性。
With FDA 510(k) submission planned in the fourth quarter of this calendar year and entry into the US market planned for the first half of the 2025 calendar year, INBS is capitalizing on the growing drug screening products market, estimated to have a total addressable market of ~$15 billion by 20301.
計劃在本日曆年第四季度提交FDA 510(k)申請，並計劃於2025年上半年進入美國市場，INBS正在利用估計到20301年將達到約150億美元的不斷增長的藥物篩查產品市場。
Fiscal First Quarter & Recent Operational Highlights:
財政第一季度及最近的運營亮點：
- On September 27, 2024, the Company announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company's clinical study plan. The clinical studies are a key element of the Company's 510(k) submission, designed to demonstrate the accuracy and reliability of its sweat-based testing method.
- 2024年9月27日，該公司宣佈成功完成了今年早些時候在公司臨床研究計劃中向FDA提出的臨床測試。這些臨床研究是公司510(k)提交的關鍵元素，設計旨在證明其基於汗液的測試方法的準確性和可靠性。
- The Company secured 22 new accounts throughout the quarter, adding to its 400+ active customer accounts in 19 countries. These new accounts have a combined total employee headcount of approximately 152,000 employees.*
- 該公司在本季度內獲得了22個新帳戶，增加了19個國家中400多個活躍客戶帳戶。這些新帳戶合計約有152,000名員工。*
- On August 1, 2024, the Company announced its partnership with CenExcel to perform a method comparison study as part of the Company's FDA 510(k) clinical study plan.
- 2024年8月1日，公司宣佈與CenExcel合作，作爲公司FDA 510(k)臨床研究計劃的一部分進行方法比對研究。
- On July 24, 2024, the Company announced QabasTech as its exclusive distributor in Saudi Arabia, marking further growth for the Company in the country.
- 2024年7月24日，公司宣佈QabasTech成爲其在沙特阿拉伯的獨家經銷商，標誌着公司在該國進一步增長。
- On July 18, 2024, the Company announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance.
- 2024年7月18日，公司宣佈其Intelligent Fingerprinting Drug Screening System的生物相容性測試成功完成，這是FDA 510(k)監管許可所需的臨床研究計劃中的關鍵階段。
Financial Results for the Fiscal 2025 First Quarter:
2025財年第一季度財務結果:
- Total cash and cash equivalents on hand as of September 30, 2024, was $3.99 million.
- 截至2024年9月30日，現金及現金等價物總計爲399萬美元。
- Shareholders equity as of September 30, 2024, was $5.95 million.
- 截至2024年9月30日，股東權益爲595萬美元。
- Total revenues for the fiscal first quarter were $0.87 million, an increase of 10% year-on-year and 20% quarter-on-quarter.
- 財務第一季度總收入爲87萬美元，同比增長10%，環比增長20%。
- Net loss for the fiscal first quarter was $2.70 million, including non-cash depreciation and amortization and share-based expenses of $0.49 million.
- 本財政第一季度淨虧損爲270萬美元，包括490,000美元的非現金折舊和攤銷費用以及股權性支出。
Revenue from sales of goods increased by $76,193 to $872,287 from $796,094 for the three months ended September 30, 2024, compared to the same period in 2023. This is due to the expansion of the customer base, both in the pre-existing markets and expansion into new regions. The Company expects this trend to continue as it expands into new markets in the future.
銷售商品的營業收入增加76,193美元，從2023年9月30日結束的三個月的796,094美元增至872,287美元，與去年同期相比。這是由於客戶群體的擴大，既包括在現有市場擴展也包括進入新區域的擴展。公司預計這一趨勢將隨着未來進入新市場的擴張而持續。
Net loss attributable to the Company increased by $0.27 million from $2.43 million to $2.70 million for the three months ended September 30, 2024, compared to the same period the year prior. This increase is primarily driven by the Company's investment in R&D work required for its FDA 510(k) clinical study plan and planned submission in the fourth quarter of this calendar year. FDA clearance would enable INBS to introduce its drug screening technology to the United States market in the 2025 calendar year.
歸屬於公司的淨虧損從2023年9月30日結束的三個月的243萬美元增至270萬美元，與去年同期相比增加了27萬美元。這一增長主要是由公司在其FDA 510(k)臨床研究計劃所需的研發工作以及計劃在本日曆年第四季度提交所驅動的。FDA的批准將使INBS能夠在2025年將其藥物篩查技術引入美國市場。
* The customer employee estimate of 152,000 employees was derived by aggregating publicly available data on the total number of employees for each INBS customer. Where employee ranges were provided, the midpoints were used for calculation. This estimate excludes customers for whom employee data is not publicly available. The total represents all employees within these organizations, including those who will not be tested using the Intelligent Fingerprinting Drug Screening System. The Company does not have the data to incorporate the percentage of employees tested using the Intelligent Fingerprinting Drug Screening System at each INBS customer. The growing customer employee base is a basic indication of the increased utilization of the Intelligent Fingerprinting Drug Screening System. The nature of work performed by certain employees or restrictions in specific jurisdictions may mean that drug testing is not necessary or applicable for all employees.
* 客戶僱員估計爲152,000名員工，是通過彙總每個INBS客戶的員工總數的公開數據計算得出的。如果提供了僱員範圍，則計算時使用中點。此估計不包括僱員數據不公開的客戶。總計包括這些組織內的所有員工，包括不會使用Intelligent Fingerprinting藥物篩查系統進行測試的員工。公司沒有數據來納入INBS每個客戶使用Intelligent Fingerprinting藥物篩查系統進行測試的員工百分比。不同員工從事的工作性質或特定法域的限制可能意味着不是所有員工都需要進行毒品測試或適用於所有員工。
Financial Tables to Follow
財務表格如下
|
Intelligent Bio Solutions Inc. Condensed Consolidated Balance Sheets* | ||||||||
| As of September 30, | As of June 30, | |||||||
| 2024 | 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 3,989,431 | $ | 6,304,098 | ||||
| Accounts receivable, net | 578,578 | 429,704 | ||||||
| Inventories, net | 738,789 | 777,537 | ||||||
| Research and development tax incentive receivable | 648,334 | 525,332 | ||||||
| Deferred charges | 127,586 | - | ||||||
| Other current assets | 396,193 | 497,572 | ||||||
| Total current assets | 6,478,911 | 8,534,243 | ||||||
| Property and equipment, net | 586,120 | 565,850 | ||||||
| Operating lease right-of-use assets | 260,760 | 306,744 | ||||||
| Intangibles, net | 4,400,092 | 4,372,026 | ||||||
| Total assets | $ | 11,725,883 | $ | 13,778,863 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 1,834,416 | $ | 1,704,568 | ||||
| Current portion of operating lease liabilities | 281,565 | 274,834 | ||||||
| Current portion of deferred grant income | 2,585,696 | 2,486,668 | ||||||
| Current employee benefit liabilities | 477,517 | 469,381 | ||||||
| Current portion of notes payable | 499,605 | 515,282 | ||||||
| Total current liabilities | 5,678,799 | 5,450,733 | ||||||
| Employee benefit liabilities, less current portion | 69,731 | 63,615 | ||||||
| Operating lease liabilities, less current portion | 28,111 | 81,324 | ||||||
| Total liabilities | $ | 5,776,641 | $ | 5,595,672 | ||||
| Commitments and contingencies | ||||||||
| Shareholders' equity | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 4,377,759 and 3,456,000 shares issued and outstanding at September 30, 2024 and June 30, 2024, respectively | 43,775 | 34,557 | ||||||
| Treasury stock, at cost, 116 shares as of September 30, 2024 and June 30, 2024, respectively | (1) | (1) | ||||||
| Additional paid-in capital | 61,207,017 | 60,971,740 | ||||||
| Accumulated deficit | (54,649,965) | (51,964,332) | ||||||
| Accumulated other comprehensive loss | (496,259) | (712,614) | ||||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 6,104,567 | 8,329,350 | ||||||
| Non-controlling interest | (155,325) | (146,159) | ||||||
| Total shareholders' equity | 5,949,242 | 8,183,191 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 11,725,883 | $ | 13,778,863 | ||||
| 智能生物解決方案股份有限公司。 簡明綜合資產負債表* | ||||||||
| 截至9月30日， | 截至6月30日， | |||||||
| 2024 | 2024 | |||||||
| (未經審計) | ||||||||
| 資產 | ||||||||
| 流動資產 | ||||||||
| 現金及現金等價物 | $ | 3,989,431 | $ | 6,304,098 | ||||
| 應收賬款，淨額 | 578,578 | 429,704 | ||||||
| 淨存貨 | 738,789 | 777,537 | ||||||
| 研發稅收減免待攤收入 | 648,334 | 525,332 | ||||||
| 遞延收費 | 127,586 | - | ||||||
| 其他流動資產 | 396,193 | 497,572 | ||||||
| 總流動資產 | 6,478,911 | 8,534,243 | ||||||
| 物業和設備，淨值 | 586,120 | 565,850 | ||||||
| 經營租賃使用權資產 | 260,760 | 306,744 | ||||||
| 無形資產，淨額 | 4,400,092 | 4,372,026 | ||||||
| 總資產 | $ | 11,725,883 | $ | 13,778,863 | ||||
| 負債和股東權益 | ||||||||
| 流動負債 | ||||||||
| 應付賬款和應計費用 | $ | 1,834,416 | $ | 1,704,568 | ||||
| 經營租賃負債流動部分 | 281,565 | 274,834 | ||||||
| 遞延撥款收入的現行部分 | 2,585,696 | 2,486,668 | ||||||
| 應付職工薪酬的現行部分 | 477,517 | 469,381 | ||||||
| 應付票據的當前部分 | 499,605 | 515,282 | ||||||
| 總流動負債 | 5,678,799 | 5,450,733 | ||||||
| 職工福利負債，減去現行部分 | 69,731 | 63,615 | ||||||
| 租賃負債，除去當前部分 | 28,111 | 1,322,841,307 | ||||||
| 總負債 | $ | 5,776,641 | $ | 5,595,672 | ||||
| 承諾和 contingencies | ||||||||
| 股東權益 | ||||||||
| 普通股，面值$0.01，全球貨幣授權100,000,000股，在2024年9月30日和2024年6月30日分別發行並流通的股份數量分別爲4,377,759股和3,456,000股 | 43,775 | 34,557 | ||||||
| 庫存股，按成本計算，在2024年9月30日和2024年6月30日分別爲116股 | (1) | (1) | ||||||
| 追加實收資本 | 61,207,017 | 60,971,740 | ||||||
| 累積赤字 | (54,649,965) | (51,964,332) | ||||||
| 累計其他綜合損失 | (496,259) | (712,614) | ||||||
| 智能生物解決方案公司的綜合股權總額 | 6,104,567 | 8,329,350 | ||||||
| 非控制權益 | (155,325) | 5,212 | ||||||
| 股東權益合計 | 5,949,242 | 8,183,191 | ||||||
| 資產負債合計 | $ | 11,725,883 | $ | 13,778,863 | ||||
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, throughout the condensed consolidated financial statements unless otherwise stated. |
| * | 普通股和每股金額已經進行了調整，以反映2024年1月26日實施的1比12的股票合併所導致的股數減少，在未另行說明的情況下貫穿於簡明綜合財務報表中。 |
|
Intelligent Bio Solutions Inc. Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)* (Unaudited) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 872,287 | $ | 796,094 | ||||
| Cost of revenue (exclusive of amortization shown separately below) | (525,486) | (563,763) | ||||||
| Gross profit | 346,801 | 232,331 | ||||||
| Other income | ||||||||
| Government support income | 126,128 | 109,871 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | (1,949,016) | (2,457,060) | ||||||
| Development and regulatory approval expenses | (948,752) | (103,947) | ||||||
| Depreciation and amortization | (300,422) | (307,560) | ||||||
| Total operating expenses | (3,198,190) | (2,868,567) | ||||||
| Loss from operations | (2,725,261) | (2,526,365) | ||||||
| Other income (expense), net | ||||||||
| Interest expense | (22,327) | (37,448) | ||||||
| Realized foreign exchange loss | (51) | - | ||||||
| Fair value gain on revaluation of financial instrument | - | 131,250 | ||||||
| Interest income | 52,840 | 139 | ||||||
| Total other income, net | 30,462 | 93,941 | ||||||
| Net loss | (2,694,799) | (2,432,424) | ||||||
| Net loss attributable to non-controlling interest | (9,166) | (7,220) | ||||||
| Net loss attributable to Intelligent Bio Solutions Inc. | $ | (2,685,633) | $ | (2,425,204) | ||||
| Other comprehensive income (loss), net of tax | ||||||||
| Foreign currency translation gain / (loss) | 216,355 | (18,016) | ||||||
| Total other comprehensive income / (loss) | 216,355 | (18,016) | ||||||
| Comprehensive loss | (2,478,444) | (2,450,440) | ||||||
| Comprehensive loss attributable to non-controlling interest | (9,166) | (7,220) | ||||||
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | (2,469,278) | (2,443,220) | ||||||
| Net loss per share, basic and diluted* | $ | (0.70) | $ | (12.48) | ||||
| Weighted average shares outstanding, basic and diluted * | 3,811,090 | 194,200 | ||||||
| 智能生物解決方案股份有限公司。 綜合損益表和其他綜合收益（虧損）* (未經審計) | ||||||||
| 截至9月30日的三個月 | ||||||||
| 2024 | 2023 | |||||||
| 收入 | $ | 872,287 | $ | 796,094 | ||||
| 營業成本（不包括下面單獨顯示的攤銷費用） | (525,486) | (563,763) | ||||||
| 毛利潤 | 346,801 | 232,331 | ||||||
| 其他收入 | ||||||||
| 政府支援收入 | 126,128 | 109,871 | ||||||
| 運營費用 | ||||||||
| 銷售、一般和管理費用 | (1,949,016) | (2,457,060) | ||||||
| 開發和監管審批費用 | (948,752) | (103,947) | ||||||
| 折舊和攤銷 | (300,422) | (307,560) | ||||||
| 總營業費用 | (3,198,190) | (2,868,567) | ||||||
| 營業損失 | (2,725,261) | (2,526,365) | ||||||
| 其他收入（費用），淨額 | ||||||||
| 利息支出 | (22,327) | (37,448) | ||||||
| 實現外匯損失 | (51) | - | ||||||
| 金融工具重新估值的公平價值收益 | - | 131,250 | ||||||
| 利息收入 | 52,840 | 139 | ||||||
| 其他收入總額，淨額 | 30,462 | 93,941 | ||||||
| 淨虧損 | (2,694,799) | (2,432,424) | ||||||
| 歸屬於少數股東的淨虧損 | (9,166) | (7,220) | ||||||
| 智能生物解決方案公司歸屬於的淨虧損 | $ | (2,685,633) | $ | (2,425,204) | ||||
| 其他綜合收入（損失），扣除稅後 | ||||||||
| 匯率期貨轉換盈利 / (虧損) | 216,355 | (18,016) | ||||||
| 其他全面收益總額 / (虧損) | 216,355 | (18,016) | ||||||
| 全面損失 | (2,478,444) | (2,450,440) | ||||||
| 非控制權益可歸因於綜合損失 | (9,166) | (7,220) | ||||||
| 智能生物解決方案公司歸屬全面虧損。 | (2,469,278) | (2,443,220) | ||||||
| 每股基本與攤薄淨虧損* | $ | (0.70) | $ | (12.48) | ||||
| 基本和稀釋後加權平均股本 * | 3,811,090 | 194,200 | ||||||
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, throughout the condensed consolidated financial statements unless otherwise stated. |
| * | 普通股和每股金額已經進行了調整，以反映2024年1月26日實施的1比12的股票合併所導致的股數減少，在未另行說明的情況下貫穿於簡明綜合財務報表中。 |
About Intelligent Bio Solutions
關於智慧生物解決方案
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
納斯達克：Intelligent Bio Solutions Inc. (INBS)是一家醫療技術公司，提供創新、快速、非侵入性的測試解決方案。該公司認爲其Intelligent Fingerprinting毒品篩查系統將通過指紋汗液分析革新便攜式測試，這具有在其他領域中有更廣泛應用潛力。設計爲衛生和經濟實惠的系統，該測試旨在篩查最近在工作場所常見的藥物使用，包括阿片類藥物、可卡因、冰毒和大麻。採樣只需幾秒鐘，結果在不到十分鐘內出來，這項技術將成爲安全關鍵行業僱主的寶貴工具。該公司目前在美國以外的客戶群包括建築、製造和工程、運輸和物流公司、藥物治療機構和法醫。
For more information, visit
要獲取更多信息，請訪問
Forward-Looking Statements
前瞻性聲明
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
智能生物解決方案股份有限公司。
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
公司聯繫人：
智能生物解決方案股份有限公司。
info@ibs.inc
領英 | 推特
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
投資者及媒體聯繫方式：
Lisa Miller
Lumos Pharma投資者 Relations
512-792-5454
ir@lumos-pharma.com
來源：Lumos Pharma, Inc。
Valter Pinto, 董事總經理
KCSA戰略傳播
電話:(212)896-1254
INBS@kcsa.com
1 Research and Markets, 2024. Drug Screening - Global Strategic Business Report. Available at:
1 研究和市場，2024年。藥物篩查-全球戰略業務報告。可在此處查看：
